

From	To	Changeover points	
		Distance	From
§ 95.8005 Jet Routes Changeover Points			
J-58 Is Amended To Add Changeover Point			
Milford, UT VORTAC .....	Farmington, NM VORTAC .....	92	Milford

[FR Doc. 02-32412 Filed 12-23-02; 8:45 am]

BILLING CODE 4910-13-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration****21 CFR Part 510****New Animal Drugs; Change of Sponsor's Address****AGENCY:** Food and Drug Administration, HHS.**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of address for Phoenix Scientific, Inc.

**DATES:** This rule is effective December 24, 2002.

**FOR FURTHER INFORMATION CONTACT:** David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6967; e-mail: dnewkirk@cvm.fda.gov.

**SUPPLEMENTARY INFORMATION:** Phoenix Scientific, Inc., 3915 South 48th St. Terrace, P.O. Box 6457, St. Joseph, MO 64506-0457, has informed FDA of a change of address to 3915 South 48th St. Terrace, St. Joseph, MO 64503. Accordingly, the agency is amending the regulations in 21 CFR 510.600 to reflect the change of sponsor's address.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to congressional review requirements in 5 U.S.C. 801-808.

**List of Subjects in 21 CFR Part 510**

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

**PART 510-NEW ANIMAL DRUGS**

1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

2. Section 510.600 is amended in the table in paragraph (c)(1) by revising the entry for "Phoenix Scientific, Inc." and in the table in paragraph (c)(2) by revising the entry for "059130" to read as follows:

**§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.**

\* \* \* \* \*

(c) \* \* \*

(1) \* \* \*

Firm name and address	Drug labeler code
* * * * *	
Phoenix Scientific, Inc., 3915 South 48th St. Ter- race, St. Joseph, MO 64503.	059130
* * * * *	

(2) \* \* \*

Drug labeler code	Firm name and address
* * * * *	
059130	Phoenix Scientific, Inc., 3915 South 48th St. Ter- race, St. Joseph, MO 64503
* * * * *	

Dated: December 4, 2002.

**Steven D. Vaughn,**

*Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*

[FR Doc. 02-32346 Filed 12-23-02; 8:45 am]

BILLING CODE 4160-01-S

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration****21 CFR Parts 510, 520, 522, and 524****New Animal Drugs; Change of Sponsor****AGENCY:** Food and Drug Administration, HHS.**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 25 approved new animal drug applications (NADAs) from American Cyanamid to Fort Dodge Animal Health.

**DATES:** This rule is effective December 24, 2002.

**FOR FURTHER INFORMATION CONTACT:**

Lonnie W. Luther, Center for Veterinary Medicine (HFV-104), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301-827-8549, e-mail: lluther@cvm.fda.gov.

**SUPPLEMENTARY INFORMATION:** American Cyanamid, Division of American Home Products, P.O. Box 1339, Fort Dodge, IA 50501, has informed FDA that it has transferred ownership of, and all rights and interest in, the following 25 approved NADAs to Fort Dodge Animal Health, Division of American Cyanamid Co., P.O. Box 1339, Fort Dodge, IA 50501:

NADA Number	Trade Name
006-084	SULMET Drinking Water Solution
008-774	SULMET Solution Injectable
011-582	VETAMOX Soluble Powder
011-644	FELAC
013-957	S.E.Z. Drinking Water 6.25%
015-160	Sodium Sulfachloropyrazine Solution
033-342	PROBAN Cythioate Tablets 30 mg
033-606	PROBAN Oral Liquid
033-653	S.E.Z. Drinking Water Solution
033-654	S.E.Z. Oblets 15 g
033-655	S.E.Z. Intravenous Solution
047-033	S.E.Z. C-R Oblets 15 g
055-012	AUREOMYCIN Sulmet Soluble Powder
055-018	AUREOMYCIN Tablets 25 mg
055-020	AUREOMYCIN Soluble Powder
055-039	AUREOMYCIN Soluble Oblets
065-071	AUREOMYCIN Soluble Powder
065-269	POLYOTIC Soluble Powder
065-270	POLYOTIC Oblets
065-313	BACIFERM Soluble 50
065-440	AUREOMYCIN Soluble Powder Concentrate
065-441	POLYOTIC Soluble Powder Concentrate
122-271	SULMET Oblets
122-272	SULMET Soluble Powder

NADA Number	Trade Name
140-844	TRAMISOL Pour-On

Accordingly, the agency is amending the regulations in 21 CFR 520.44, 520.154c, 520.445a, 520.445b, 520.445c, 520.530, 520.531, 520.2184, 520.2240a, 520.2240b, 520.2260a, 520.2261a, 520.2261b, 520.2345c, 520.2345d, 522.940, 522.2240, 522.2260, and 524.1240 to reflect the transfer of ownership and to reflect current format.

Following this change of sponsorship, American Cyanamid is no longer the sponsor of any approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for American Cyanamid.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

#### List of Subjects

##### 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

##### 21 CFR Parts 520, 522, and 524

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, and 524 are amended as follows:

#### PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

##### § 510.600 [Amended]

2. Section 510.600 *Names, addresses, and drug labeler codes of sponsors of approved applications* is amended in the table in paragraph (c)(1) by removing the entry for "American Cyanamid" and in the table in paragraph (c)(2) by removing the entry for "010042".

#### PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

3. The authority citation for 21 CFR part 520 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

##### § 520.44 [Amended]

4. Section 520.44 *Acetazolamide sodium soluble powder* is amended in paragraph (b) by removing "010042" and by adding in its place "053501".

##### § 520.154c [Amended]

5. Section 520.154c *Bacitracin zinc soluble powder* is amended in paragraph (b) by removing "010042" and by adding in its place "053501".

##### § 520.445a [Amended]

6. Section 520.445a *Chlortetracycline bisulfate/sulfamethazine bisulfate soluble powder* is amended in paragraph (b) by removing "010042" and by adding in its place "053501".

##### § 520.445b [Amended]

7. Section 520.445b *Chlortetracycline powder (chlortetracycline hydrochloride or chlortetracycline bisulfate)* is amended in paragraphs (b) and (d)(4)(iii)(C) by removing "010042" and by adding in its place "053501".

##### § 520.445c [Amended]

8. Section 520.445c *Chlortetracycline tablets and boluses* is amended in paragraph (b) by removing "010042" and by adding in its place "053501".

##### § 520.530 [Amended]

9. Section 520.530 *Cythioate oral liquid* is amended in paragraph (b) by removing "010042" and by adding in its place "053501".

##### § 520.531 [Amended]

10. Section 520.531 *Cythioate tablets* is amended in paragraph (b) by removing "010042" and by adding in its place "053501".

##### § 520.2184 [Amended]

11. Section 520.2184 *Sodium sulfachloropyrazine monohydrate* is amended in paragraph (b) by removing "010042" and by adding in its place "053501".

##### § 520.2240a [Amended]

12. Section 520.2240a *Sulfaethoxypyridazine drinking water* is amended in paragraph (c) by removing "010042" and by adding in its place "053501".

##### § 520.2240b [Amended]

13. Section 520.2240b *Sulfaethoxypyridazine tablets* is amended in paragraph (c) by removing "010042" and by adding in its place "053501".

##### § 520.2260a [Amended]

14. Section 520.2260a *Sulfamethazine oblet, tablet, and bolus* is amended in paragraph (a)(1) by removing "010042" and by adding in its place "053501".

##### § 520.2261a [Amended]

15. Section 520.2261a *Sulfamethazine sodium drinking water solution* is amended in paragraph (a) by removing "010042" and by adding in its place "053501".

##### § 520.2261b [Amended]

16. Section 520.2261b *Sulfamethazine sodium soluble powder* is amended in paragraph (a) by removing "010042" and by adding in its place "053501".

##### § 520.2345c [Amended]

17. Section 520.2345c *Tetracycline boluses* is amended in paragraph (b) in the first sentence by removing "010042" and by adding in its place "053501".

##### § 520.2345d [Amended]

18. Section 520.2345d *Tetracycline hydrochloride soluble powder* is amended in paragraphs (a)(3), (d)(1)(iii), and (d)(2)(iii) by removing "010042" and by adding in its place "053501".

#### PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

19. The authority citation for 21 CFR part 522 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

##### § 522.940 [Amended]

20. Section 522.940 *Colloidal ferric oxide injection* is amended in paragraph (c)(1) by removing "010042 and 017800" and by adding in its place "017800 and 053501".

##### § 522.2240 [Amended]

21. Section 522.2240 *Sulfaethoxypyridazine* is amended in paragraph (c) by removing "010042" and by adding in its place "053501".

##### § 522.2260 [Amended]

22. Section 522.2260 *Sulfamethazine injectable solution* is amended in paragraph (b) by removing "010042" and by adding in its place "053501".

#### PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

23. The authority citation for 21 CFR part 524 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

##### § 524.1240 [Amended]

24. Section 524.1240 *Levamisole* is amended in paragraph (b) by removing "010042" and by adding in its place "053501".

Dated: November 8, 2002.

**Steven D. Vaughn,**

*Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*  
[FR Doc. 02-32345 Filed 12-23-02; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### 21 CFR Part 520

#### Oral Dosage Form New Animal Drugs; Lincomycin Hydrochloride Soluble Powder

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental abbreviated new animal drug application (ANADA) filed by Alpharma, Inc. The supplemental ANADA provides for reducing the preslaughter withdrawal time to zero days for use of lincomycin soluble powder in medicated drinking water for swine.

**DATES:** This rule is effective December 24, 2002.

**FOR FURTHER INFORMATION CONTACT:**

Janis R. Messenheimer, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7578, e-mail: jmessenh@cvm.fda.gov.

**SUPPLEMENTARY INFORMATION:** Alpharma, Inc., One Executive Dr., P.O. Box 1399, Fort Lee, NJ 07024, filed a supplement to ANADA 200-189 for Lincomycin (lincomycin HCl) Soluble requesting a reduction in the preslaughter withdrawal time to zero days for use of lincomycin soluble powder in medicated drinking water for swine. The supplemental ANADA is approved as of September 19, 2002, and the regulations are amended in § 520.1263c (21 CFR 520.1263c) to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9

a.m. and 4 p.m., Monday through Friday.

The agency has determined under § 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

#### List of Subjects in 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

#### PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

#### § 520.1263c [Amended]

2. Section 520.1263c *Lincomycin hydrochloride soluble powder* is amended in paragraph (d)(1)(iii) by removing "Nos. 046573 and 051259" and by adding in its place "No. 051259".

Dated: December 5, 2002.

**Steven D. Vaughn,**

*Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*  
[FR Doc. 02-32343 Filed 12-23-02; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### 21 CFR Parts 520 and 556

#### Oral Dosage Form New Animal Drugs; Florfenicol

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Schering-Plough Animal Health Corp. The NADA provides for use of a florfenicol concentrate solution to make medicated

drinking water for administration to swine for the treatment of respiratory disease. FDA is also amending the regulations to add tolerances for residues of florfenicol in edible tissues of swine.

**DATES:** This rule is effective December 24, 2002.

**FOR FURTHER INFORMATION CONTACT:** Joan C. Gotthardt, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7571, e-mail: jgotthar@cvm.fda.gov.

**SUPPLEMENTARY INFORMATION:** Schering-Plough Animal Health Corp., 1095 Morris Ave., Union, NJ 07083, filed NADA 141-206 for NUFLO (florfenicol) 2.3% Concentrate Solution used to make medicated drinking water for administration to swine for the treatment of respiratory disease associated with several bacterial pathogens. The NADA is approved as of September 4, 2002, and the regulations are amended in 21 CFR part 520 by adding § 520.955 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In addition, the regulations are amended in 21 CFR 556.283 to establish tolerances for residues of florfenicol in edible tissues of treated swine and to reflect a current format.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for 3 years of marketing exclusivity beginning September 4, 2002.

The agency has determined under 21 CFR 25.33(d)(5) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.